Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2020-08-13 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
前次募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report titled "前次募集资金使用情况鉴证报告" which translates to "Verification Report on the Use of Previous Fundraising Proceeds." It includes an auditor's verification opinion, references to Chinese regulatory requirements from the China Securities Regulatory Commission (CSRC), and detailed financial and operational data related to the use of funds raised in a prior capital raising event. The document contains audited financial data, management responsibilities, auditor responsibilities, and a conclusion on the accuracy of the fundraising use report. It also includes attachments with detailed tables on the use of funds and the performance of investment projects. This type of document is a standalone audit or verification report focused on the use of capital raised, not a full annual or interim report. It is not an announcement or a brief summary but a substantive verification report. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2019
2020-08-13 Chinese
监事会关于公司2020年度非公开发行股票的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's 2020 non-public issuance of shares. It references compliance with Chinese securities laws and regulations, discusses the issuance plan, fundraising use, and supervisory board review. The content focuses on the approval and oversight of a capital raising activity rather than presenting financial statements or audit results. The document length is short (993 characters) and is a formal opinion on a financing event. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to non-public stock issuance and fundraising activities.
2020-08-13 Chinese
独立董事关于公司第九届董事会第一次会议相关事项的事前认可意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' pre-approval opinion regarding the company's non-public issuance of A shares, including compliance with relevant laws and regulations, feasibility analysis, and authorization for related matters. It is not a full report but a formal opinion document related to board meeting agenda items concerning capital raising activities. The document length is short (1911 characters) and focuses on approval opinions rather than detailed financial data or full report content. This fits best under Capital/Financing Update (CAP) as it relates to non-public stock issuance and financing plans.
2020-08-13 Chinese
关于召开2020年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for convening the 2020 second extraordinary general meeting of shareholders of a company, including meeting time, voting procedures, agenda items, and proxy forms. It focuses on shareholder meeting logistics and proposals related to non-public stock issuance and related authorizations. There are no financial statements, earnings data, or management discussion of results. It is not a report but a formal meeting notice and voting instructions. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-08-13 Chinese
关于最近五年被证券监管部门和交易所采取监管措施或处罚的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the absence of regulatory penalties or measures taken against it in the past five years. It mentions compliance with securities regulations and is related to an application for a non-public stock issuance. The document is short (637 characters) and serves as a regulatory disclosure rather than a detailed financial report or audit. It does not contain financial statements, audit results, or management discussion. It fits best under Regulatory Filings (RNS) as a compliance disclosure related to regulatory status and stock issuance application.
2020-08-13 Chinese
独立董事关于公司第九届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the company's ninth board meeting held on August 13, 2020. It discusses the appointment of senior management, the company's qualification for a non-public stock issuance, the stock issuance plan, feasibility analysis of fund usage, measures to mitigate dilution impact, previous fundraising usage, and authorization for handling the stock issuance. The content focuses on board meeting matters and independent directors' opinions on these corporate governance and financing issues. It is not a full financial report, earnings release, or audit report. It is not a simple announcement or certification but a detailed opinion related to board decisions and management appointments. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in board or senior management and related governance matters.
2020-08-13 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.